mRNA Synthesis Raw Materials Market Size, Share and Trends Report 2025 to 2034
Share With :
Global mRNA Synthesis Raw Materials Market Size is valued at USD 1.8 Bn in 2024 and is predicted to reach USD 3.4 Bn by the year 2034 at a 6.6% CAGR during the forecast period for 2025 to 2034.
mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes, Others), By Application (Vaccine Production, Therapeutics Production, Others), By End-user (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes), By Region, and Segment Forecasts, 2025 to 2034
Key Industry Insights & Findings from the Report:
The mRNA synthesis raw material market revolves around the essential ingredients needed to produce messenger RNA (mRNA). Significant raw materials include nucleotides (the building blocks), enzymes (which help construct the mRNA), capping agents (that protect the message), and modified bases (to enhance performance). This market study encompasses companies that manufacture and supply these materials to biotech firms, pharmaceutical manufacturers, and research laboratories.
mRNA vaccines are more efficacious, have better immunogenicity, and cost less to produce than traditional treatments. For the projection period, mRNA synthesis and production services are anticipated to have rapid market expansion due to ongoing breakthroughs and advancements. Due to the key market players' goal of providing superior quality and efficacy products, there is an increasing demand for high-quality raw materials for efficient mRNA synthesis. This is essential for developing safe and effective pharmaceutical goods, vaccines, and medications. Key competitors' alliances, acquisitions, and partnerships to increase the supply of raw materials also drive the industry. The market is expanding due to new pharmaceutical companies' inventions, improved medical technology, and greater customization of facilities and services with higher quality and effectiveness.
The mRNA synthesis raw materials market is segmented into type, application, and end-user. Based on type, the market is segmented into capping agents, nucleotides, plasmid DNA, enzymes, and others. Based on the application, the market is divided into vaccine production, therapeutics production, and others. Based on the End-user, the market is divided into biopharmaceutical and pharmaceutical companies, cross and CMOS, and academic and research institutes.
Based on type, the market is segmented into capping agents, nucleotides, plasmid DNA, enzymes, and others. Among these, the capping agents’ segment is expected to have the highest growth rate during the forecast period. Capping agents are critical for mRNA stability, translation efficiency, and reduced immunogenicity, making them essential components in the synthesis of functional, therapeutic-grade mRNA. They play a vital role in the formation of the 5' cap structure, which is crucial for effective mRNA translation. The demand for capping agents has grown significantly with the expanding use of mRNA technologies in vaccines, gene therapies, and personalized medicines. This segment is further driven by innovations in cap analogs and enzymatic capping kits, which enhance the efficiency and safety of mRNA products. In comparison, nucleotides including modified variants like N1-methyl-pseudouridine are also used in large volumes but have a relatively lower unit cost, making their overall market share smaller despite their importance in mRNA synthesis.
Based on the application, the market is divided into vaccine production, therapeutics production, and others. Among these, the vaccine production segment dominates the market. Vaccine production is the major demand driver in the mRNA synthesis raw materials market, especially in the post-COVID-19 era. The success of mRNA-based vaccines during the pandemic has accelerated research and development efforts, leading to a strong pipeline of mRNA vaccines targeting infectious diseases such as influenza, RSV, and HIV. This segment continues to be supported by government funding and global health initiatives aimed at pandemic preparedness and public health. While therapeutics production is rapidly growing, it remains an emerging segment, primarily focused on oncology, rare diseases, and genetic disorders. Although its current volume is smaller compared to vaccines, it holds significant growth potential due to increasing investments and clinical advancements.
North America is home to leading biotech and pharmaceutical companies, making it a major hub for the consumption and production of mRNA synthesis raw materials. The region boasts a well-established research ecosystem supported by top universities, advanced research institutes, and substantial funding from both public agencies, such as the NIH and BARDA, as well as private investors. Additionally, strong regulatory support for mRNA technologies through mechanisms like FDA fast-tracks and Emergency Use Authorizations has accelerated development timelines and market access. Combined with significant investments in pandemic preparedness and biotechnology innovation, these factors have firmly positioned North America as the dominant region in the mRNA synthesis raw materials market.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 1.8 Billion |
| Revenue Forecast In 2034 | USD 3.4 Billion |
| Growth Rate CAGR | CAGR of 6.6% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, By Application, By End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | F. Hoffmann-La Roche Ltd., Jena Bioscience GmbH, Merck KGaA, Yeasen Biotechnology (Shanghai) Co., Ltd., BOC Sciences, Thermo Fisher Scientific, Inc., Maravai LifeSciences, New England Biolabs, Creative Biogene, HONGENE |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
mRNA Synthesis Raw Materials Market - By Type
mRNA Synthesis Raw Materials Market – By Grade Type
mRNA Synthesis Raw Materials Market – By Application
mRNA Synthesis Raw Materials Market – By End-user
mRNA Synthesis Raw Materials Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.